Individuals Coming Off Anti-Obesity Medications Gain Back Weight Far More Rapidly Than Those on Conventional Diets

New research suggests that patients who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.

Research printed in a leading medical journal points out that while overweight individuals can lose a large proportion of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.

"Individuals buying these medications should be aware of the potential of quick weight regain when the medication concludes," warns researcher Dr. Susan Jebb.

That rate of regain suggests a return to starting weight in about a year and a half.

Weighing Treatments

The research, which reviewed 37 of studies involving over 9,000 of patients, compared the results of the injectable medications with other pills.

Scientists emphasize that people who lose weight through dieting typically have a slower weight regain—around 100 grams monthly—post-intervention.

Understanding the Rapid Regain

Nutrition scientists propose the way of the injections is key to understanding the heightened rebound.

The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing the hormone levels several times higher than normal might result in the body to produce less of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this hormone supplement leads to hunger is no longer kept in check, making binge eating a significant risk."

A Lifelong Condition?

The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.

Many experts argue that, due to the significant potential of relapse, the therapy might need to be life-long.

This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of excess weight," akin to managing conditions like high blood pressure.

User Experiences

Individuals who have stopped the jabs report a sudden return of hunger.

"It was like something that goes on and I was suddenly starving," said one woman.

This difficulty is exacerbated if patients have not adopted lasting dietary or behavioural modifications during treatment.

Significant Adoption

Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.

• Adoption is greater among females than males.
• The middle-aged demographic shows the highest usage rates.
• A large proportion obtain the drugs through private healthcare rather than public health services.

Finally, researchers caution that while the jabs are powerful tools for weight loss, they are not a standalone fix and maintained weight loss hinges on ongoing behavioural support.